BR112023015472A2 - Métodos para fazer formas transisoméricas de moduladores de receptores acoplados à proteína g - Google Patents

Métodos para fazer formas transisoméricas de moduladores de receptores acoplados à proteína g

Info

Publication number
BR112023015472A2
BR112023015472A2 BR112023015472A BR112023015472A BR112023015472A2 BR 112023015472 A2 BR112023015472 A2 BR 112023015472A2 BR 112023015472 A BR112023015472 A BR 112023015472A BR 112023015472 A BR112023015472 A BR 112023015472A BR 112023015472 A2 BR112023015472 A2 BR 112023015472A2
Authority
BR
Brazil
Prior art keywords
transisomeric
methods
forms
coupled receptor
receptor modulators
Prior art date
Application number
BR112023015472A
Other languages
English (en)
Portuguese (pt)
Inventor
Ashkaan Younai
Cyril Bucher
J Wustrow David
Grant Shibuya
P Davidson James
J Jackson Jeffrey
Yoo Min Ko Michelle
Mikhail Zibinsky
Original Assignee
Rapt Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rapt Therapeutics Inc filed Critical Rapt Therapeutics Inc
Publication of BR112023015472A2 publication Critical patent/BR112023015472A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Hydrogenated Pyridines (AREA)
BR112023015472A 2021-02-02 2022-01-28 Métodos para fazer formas transisoméricas de moduladores de receptores acoplados à proteína g BR112023015472A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163144878P 2021-02-02 2021-02-02
PCT/US2022/014450 WO2022169696A1 (en) 2021-02-02 2022-01-28 Methods of making trans isomeric forms of g protein-coupled receptor

Publications (1)

Publication Number Publication Date
BR112023015472A2 true BR112023015472A2 (pt) 2023-11-07

Family

ID=80446466

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023015472A BR112023015472A2 (pt) 2021-02-02 2022-01-28 Métodos para fazer formas transisoméricas de moduladores de receptores acoplados à proteína g

Country Status (12)

Country Link
US (2) US12428393B2 (https=)
EP (1) EP4288425A1 (https=)
JP (1) JP2024505561A (https=)
KR (1) KR20230152027A (https=)
CN (1) CN116940564A (https=)
AU (1) AU2022216216A1 (https=)
BR (1) BR112023015472A2 (https=)
CA (1) CA3209122A1 (https=)
IL (1) IL304519A (https=)
MX (1) MX2023009053A (https=)
TW (1) TW202246236A (https=)
WO (1) WO2022169696A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5772680A (en) 1992-06-02 1998-06-30 General Surgical Innovations, Inc. Apparatus and method for developing an anatomic space for laparoscopic procedures with laparoscopic visualization

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10246462B2 (en) * 2016-09-09 2019-04-02 Flx Bio, Inc. Chemokine receptor modulators and uses thereof
DK3743418T3 (da) * 2018-01-26 2024-09-09 Rapt Therapeutics Inc Chemokinreceptormodulatorer og anvendelser deraf

Also Published As

Publication number Publication date
TW202246236A (zh) 2022-12-01
WO2022169696A8 (en) 2023-08-31
IL304519A (en) 2023-09-01
US12428393B2 (en) 2025-09-30
AU2022216216A1 (en) 2023-08-03
CN116940564A (zh) 2023-10-24
JP2024505561A (ja) 2024-02-06
US20260092049A1 (en) 2026-04-02
CA3209122A1 (en) 2022-08-11
MX2023009053A (es) 2023-10-16
WO2022169696A1 (en) 2022-08-11
US20220251070A1 (en) 2022-08-11
KR20230152027A (ko) 2023-11-02
EP4288425A1 (en) 2023-12-13
AU2022216216A9 (en) 2024-05-23

Similar Documents

Publication Publication Date Title
MX2024001768A (es) Cartucho y aparato de formacion de imagen.
CL2023003614S1 (es) Visor montado en cabeza.
CL2022001271A1 (es) Agonista del receptor glp-1 y uso de este
CY1123226T1 (el) Ενωσεις 4,6-διαμινο-πυριδο[3,2-d]πυριμιδινης και χρηση αυτων ως ρυθμιστες toll-τυπου υποδοχεων
ECSP21025707A (es) Anticuerpos estabilizadores de trem2
MA54136A (fr) Système de projection pour affichage tête haute (hud) à rayonnement polarisé p
PE20211696A1 (es) Moleculas agonistas de union al antigeno cd28 que actuan sobre el tumor
CU24487B1 (es) Compuestos de tetrahidroquinolinona sustituidos como moduladores de gamma ror
CL2016002547A1 (es) Anticuerpos contra her2 biespecíficos
CR20180163A (es) Anticuerpos biespecíficos específicos para un receptor de tnf coestimulador
CO2018013827A2 (es) Procesos para preparar oligómeros de morfolino fosforodiamidato
MX2019000738A (es) Sistema de visualizacion superior para representar informacion de imagenes para un observador.
BR112022008061A2 (pt) Processo eficaz para síntese de 2-amino-5-cloro-n,3-dimetilbenzamida
CL2018003515A1 (es) Anticuerpos anti-gitr y sus usos.
MX2021011008A (es) Compuestos piperidinil biciclicos fusionados y relacionados como modulares del receptor c5a.
BR112023015472A2 (pt) Métodos para fazer formas transisoméricas de moduladores de receptores acoplados à proteína g
MX2022003168A (es) Metodo, dispositivo y aparato de codificacion y decodificacion.
MX2017006448A (es) 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de receptor acoplado a proteina g 139 (gpr139).
AR114110A1 (es) Anticuerpo anti-trka
CO2018013834A2 (es) Procesos para preparar oligómeros de morfolino fosforodiamidato
MX2021000278A (es) Sintesis enzimatica de analogos de nucleosido de 4'-etinilo.
MX387454B (es) DsbA Y DsbC ULTRAPURIFICADO Y MÉTODOS PARA ELABORARLOS Y UTILIZARLOS.
CO2025010244A2 (es) Anticuerpos multiespecíficos y usos de estos
CO2018013831A2 (es) Procesos para preparar oligómeros de morfolino fosforodiamidato
MX2023008634A (es) Análogos de rapamicina y usos de estos.